If you enjoy this content, please share it with a colleague
RELATED CONTENT
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company's new one-vial Oncardia (ethylenedicysteine-glucosamine) kits. The 60-patient trial study is being conducted in the U.S.
July 7, 2016 — Cell>Point announced in mid-June it has entered into an exclusive license agreement for China, Hong Kong ...
News
March 15, 2012 - Cell>Point announced that it has received a letter from the U.S. Food and Drug Administration (FDA) indicating agreement on a Special Protocol Assessment (SPA) for Cell>Point’s Phase 3 pivotal clinical study of technetium-99m-EC-G in lung cancer.